Dyne Therapeutics, Inc. Reclassifications of Temporary to Permanent Equity
Dyne Therapeutics, Inc. (DYN) reported Reclassifications of Temporary to Permanent Equity of $33.75 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-04.
Discontinued › Shareholders' Equity
us-gaap:ReclassificationsOfTemporaryToPermanentEquity · last filed 2021-03-04
- Dyne Therapeutics, Inc. reclassifications of temporary to permanent equity for the quarter ending 2019-09-30 was $33.75M.
- Dyne Therapeutics, Inc. reclassifications of temporary to permanent equity for fiscal 2019 was $33.75M.
| Period end | Reclassifications of Temporary to Permanent Equity 3 month | Reclassifications of Temporary to Permanent Equity 12 month |
|---|---|---|
| 2019-12-31 | $33.75M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $33.75M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |